Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0U4SM
|
|||
| Former ID |
DIB016989
|
|||
| Drug Name |
NASVAC
|
|||
| Synonyms |
NASTERAP; HBV vaccine (intranasal), CIGB
Click to Show/Hide
|
|||
| Drug Type |
Vaccine
|
|||
| Indication | Hepatitis B virus infection [ICD-11: 1E51.0; ICD-10: B18.1] | Phase 3 | [1] | |
| Company |
Center for Genetic Engineering and Biotechnology
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Hepatitis B virus Large envelope protein (HBV S) | Target Info | . | [2] |
| Natural killer cell receptor (NKCR) | Target Info | . | [2] | |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035019) | |||
| REF 2 | In vitro stimulation with HBV therapeutic vaccine candidate Nasvac activates B and T cells from chronic hepatitis B patients and healthy donors. Mol Immunol. 2015 Feb;63(2):320-7. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.